This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
At the beginning of 2023, the PPD clinical research business of Thermo Fisher Scientific surveyed 120 drugdevelopers across the pharmaceutical, biopharmaceutical and biotechnology sectors (referred to collectively as “pharma”) to learn more about sponsors’ current needs for site and patient recruitment services.
As pharmacompanies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. Download Medidata’s white paper to learn how to virtualize clinical trials and bring new therapies closer to patients.
Phages that can be essentially downloaded and synthesized by anyone, in any location, would solve those problems, he says. Of course, the models for low and middle-income countries will be heavily reliant on public or philanthropic funding, rather than the profit incentive that drives so much drugdevelopment in the West.
Planning the journey from data to deliverables The future of AI-enabled drugdevelopment benefits from the continued advancement of multimodality and clinical genomics, with a focus on integration, efficiency and personalisation to transform both care and R&D. Techbio companies have initiated this approach.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content